follitropin alfa + choriogonadotropin alfa + gonadotropin-releasing hormone agonist

This is a **combination product** comprising follitropin alfa (recombinant follicle-stimulating hormone, FSH), choriogonadotropin alfa (recombinant human chorionic gonadotropin, hCG), and a gonadotropin-releasing hormone (GnRH) agonist, intended for use in **controlled ovarian stimulation protocols** for assisted reproductive technologies, such as in vitro fertilization (IVF). Follitropin alfa promotes ovarian follicular growth and maturation by mimicking endogenous FSH. Choriogonadotropin alfa mimics the natural LH surge to induce final oocyte maturation and ovulation. The GnRH agonist suppresses premature LH surges (preventing premature ovulation) and allows timing control during the stimulation cycle. The combination is used to induce the development of multiple follicles, coordinate timing for egg retrieval, and enhance ART success rates[1][3][7]. This triple combination is under investigation as a "unitary combination of FSH and hCG" with the addition of a GnRH agonist to optimize ovarian stimulation outcomes, but it is not an approved marketed drug as a fixed-dose combination. Clinical research is ongoing regarding optimal doses and combinations for best outcomes[1][3].